B
Bull
Bull · 25%PHAR
$11.40
Precio del escenario
$11.700
-0.080 (-0.68%)Al cierre
Loading chart…
- High
- 11.810
- Open
- 11.810
- VWAP
- 11.71
- Vol
- 9.45K
- Mkt Cap
- 529.32M
- Low
- 11.628
- Amount
- 110.64K
- EV/EBITDA, TTM
- 43.13
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
AI analysis of Pharming Group NV (PHAR)
buyPharming Group NV (PHAR) is a good buy right now due to its current price of $1.10, which is significantly below the average analyst price target of $2.21, suggesting a potential upside of 101.33%. Additionally, despite a recent revenue estimate downgrade, the expected earnings per share for the full year has improved from $0.03 to $0.05, indicating potential profitability growth. The main risk is the forward P/E ratio of 277.78, which indicates high valuation expectations that may not be met if performance does not improve as anticipated.
Métricas de valoración
The current forward P/E ratio for Pharming Group NV (PHAR) is 277.78, compared to its 5-year average forward P/E of -44.91.
Alphio AI Price Scenarios for PHAR
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.508-13NewsfilterJoenja® Launches in Japan for Pediatric Patients
9.508-07PRnewswirePharming Group Lowers 2026 Revenue Guidance, Shares Plunge
7.008-05Yahoo FinanceShore Capital Discloses Trading Details for Pharos Energy
- 1.008-04Newsfilter
Pharming Group to Participate in Growth Conference
9.508-03PRnewswirePharming Group Lowers 2026 Revenue Guidance, Shares Plunge
PHAR FAQ — answered by Alphio AI
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization. It operates in the Healthcare sector.
Pharming Group NV (PHAR) is a good buy right now due to its current price of $1.10, which is significantly below the average analyst price target of $2.21, suggesting a potential upside of 101.33%. Additionally, despite a recent revenue estimate downgrade, the expected earnings per share for the full year has improved from $0.03 to $0.05, indicating potential profitability growth. The main risk is the forward P/E ratio of 277.78, which indicates high valuation expectations that may not be met if performance does not improve as anticipated.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.